14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Tue, 7 May 2024

Trading levels for ACOR

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 0.661 .
R2 0.661 .
R1 0.661 .
Current price: 0.661
Support S1 0.661 .
S2 0.661 .
S3 0.661 .

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 0 .
R2 0 .
R1 0 .
Current price 0.661
Support S1 0 .
S2 0 .
S3 0 .

ACOR Predictions History

4 years ago
YukonY predicted that ACOR for 2019-08-22 is going $3.00 (-4.46%)

Rank:

4 years ago
Joel predicted that ACOR for 2019-08-22 is going $3.30 (5.10%)

Rank:

4 years ago
YukonY predicted that ACOR for 2019-08-20 is going $3.12 (6.48%)

Rank:

4 years ago
YukonY predicted that ACOR for 2019-08-19 is going $2.89 (7.04%)

Rank:

4 years ago
JS predicted that ACOR for 2019-08-15 is going $2.13 (-18.70%)

4 years ago
JS predicted that ACOR for 2019-08-14 is going $2.57 (7.53%)

4 years ago
Tricia.Saucier.118720 predicted that ACOR for 2019-08-14 is going $7.26 (165.93%)

Rank:

4 years ago
YukonY predicted that ACOR for 2019-08-14 is going $2.66 (-2.56%)

Rank:

5 years ago
NameNotImportant predicted that ACOR for 2019-05-01 is going $10.18 (1.29%)

5 years ago
NameNotImportant predicted that ACOR for 2019-04-30 is going $11.33 (8.42%)

Click to get the best stock tips daily for free!

About Acorda Therapeutics

Acorda Therapeutics Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS p... ACOR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT